{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:50:41Z","timestamp":1762505441087},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1097\/qai.0b013e31819367fc","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T08:14:49Z","timestamp":1232439289000},"page":"192-195","source":"Crossref","is-referenced-by-count":5,"title":["Changes in Darunavir\/r Resistance Score After Previous Failure to Tipranavir\/r in HIV-1-Infected Multidrug-Resistant Patients"],"prefix":"10.1097","volume":"50","author":[{"given":"Vincenzo","family":"Spagnuolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Seminari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Fusetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Salpietro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210131","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","article-title":"Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"R2-10-20210131","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R3-10-20210131","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1073\/pnas.92.6.2398","article-title":"Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.","volume":"92","author":"Shirasaka","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-10-20210131","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/infdis\/174.5.962","article-title":"Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.","volume":"174","author":"Schmit","year":"1996","journal-title":"J Infect Dis"},{"key":"R5-10-20210131","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/JVI.70.2.1086-1090.1996","article-title":"Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.","volume":"70","author":"Iversen","year":"1996","journal-title":"J Virol"},{"key":"R6-10-20210131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1086\/381097","article-title":"Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.","volume":"38","author":"Zaccarelli","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R9-10-20210131","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1128\/JVI.00712-06","article-title":"Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.","volume":"80","author":"Baxter","year":"2006","journal-title":"J Virol"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200902010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:23:43Z","timestamp":1618039423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200902010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31819367fc","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}